Destiny Pharma Plc (DEST.L) Announced, in its unaudited interim financial results for the half-year ended 30 June 2020, that operating losses increased to £3.0 million from £2.5 million recorded in the same period previous year. Loss after tax widened to £2.4 million from £2.1 million. Separately, announced an update on it its XF73 Phase 2b clinical study with 88 patients out of the target of 125 now recruited. There is good momentum in patient recruitment which we expect to continue into the Autumn. The Phase 2b clinical study is recruiting patients undergoing open heart surgery in United States and Europe. Barring any further impact from COVID-19 the study is on plan to complete recruitment by the end of 2020 and report results in Q1 2021. #DEST
#DEST ''Plenty of progress in H1'' - Having navigated the challenge of running a clinical trial during a global pandemic, Destiny has blossomed in mid-2020. It is on track to announce top-line Phase 2b results for XF-73 in the prevention of post-surgical infections in Q1 2021. It has also expanded its pipeline to span the two most contemporary issues in biotech: the microbiome and the prevention of COVID-19 infections. Cash at the end of H1 2020 was £5.6m (£9.1m at the end of H1 2019) and in-line with our estimates. The company’s cash runway now extends to the end of 2021 which should be more than enough time to partner XF-73 after positive Phase 2b results in Q1 2021. Destiny have weathered the challenges of clinical trial recruitment and management during the global pandemic that led other companies to abandon their studies. The Phase 2b study continues to recruit, with 88 of the 125-patient FDA-agreed target already on board and having breezed through the interim independent safety review. We value Destiny Pharma at £84.5m, or 193p per share. - Read Full Note here:
RNS Number: 2261 Z Destiny Pharma PLC 17 September 2020 Destiny Pharma plc. Brighton, United Kingdom- 17 September 2020- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections today announces an update on it its XF-73 Phase 2 b clinical study with 88 patients out of the...
RNS Number: 2268 Z Destiny Pharma PLC 17 September 2020. Interim results for the six months ended 30 June 2020. Brighton, United Kingdom- 17 September 2020- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces its unaudited interim financial results for the...
RNS Number: 5360 Y Destiny Pharma PLC 10 September 2020 Destiny Pharma plc. Brighton, United Kingdom- 10 September 2020- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance, will announce its financial results for...
#DEST ''Another string to Destiny's bow'' - Destiny Pharma have always had a microbiome tilt with their most advanced product, topical XF-73, being developed for the prevention of post-operative infections. But now, with a new collaboration and grant award for the SPOR-COV program, they have taken this even further to encompass the two hot-button issues in anti-infectives: the microbiome and coronavirus infections. Now Destiny’s discovery efforts and pipeline have been expanded with the SPOR-COV collaboration and grant award with SporeGen and the University of Liverpool. This allows them to investigate (another) preventative effect of, in this case, a nasally delivered Bacillus formulation developed by SporeGen to stimulate the innate immunity against coronavirus.This positive development plays to Destiny’s strengths in topical (nasal) administration, preventative indications, as well as the cost-effective management of its earlier-stage pipeline which we described in our recent initiation note. The development of SporeGen’s technology as a preventative therapy for COVID-19 has many advantages over traditional vaccines.There are no changes to our model arising from the announcement of the SPOR-COV early-stage pipeline development. We retain our valuation of Destiny Pharma at £86.3m, or 197p per share. - Read full analysis here:
Destiny Pharma Plc (DEST.L) Announced that it has entered into a collaboration agreement with SporeGen Limited (SporeGen), a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen's SPOR-COV product as a novel, preventive treatment for COVID-19. #DEST
RNS Number: 1521 Y Destiny Pharma PLC 07 September 2020 Destiny Pharma and SporeGen ® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19. ·Innovate UK grant of £800,000 to support SPOR-COV programme over the next 18 months. Brighton, United Kingdom- 7 September 2020- Destiny Pharma plc, a clinical stage...
RNS Number: 7053 V Destiny Pharma PLC 11 August 2020 Destiny Pharma plc. Positive interim safety review of Phase 2 b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections. Brighton, United Kingdom- 11 August 2020- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel treatments for...
Destiny Pharma Plc #DEST announced a clinical protocol amendment has been agreed with FDA for its ongoing phase 2b study of lead asset XF-73. The study is evaluating XF-73, as a nasal gel, for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, such as MRSA. The agreed amendment recognizes the impact COVID-19 has had in slowing patient recruitment in clinical studies since March and the FDA's willingness to support certain protocol amendments that help to accelerate the completion of ongoing clinical trials but do not compromise a study's integrity and clinical objectives. The amendment to the protocol incorporates a change to the primary patient population where the primary endpoint for the study will be measured. The primary microbiological endpoint postsurgery will now be measured in those patients who had a positive load of nasal Staphylococcus aureus before receiving the study treatment. Destiny Pharma expects that as the incidence of COVID19 continues to decline in European hospitals they will begin recruiting patients into the study again and that recruitment into US study sites is likely to lag, given the higher infection incidence. That said, the study has already enrolled 77 patients out of the new target of 125 and the Company expects to have over 20 sites open in three countries actively recruiting the remaining patients in the next few months with the majority of these being FDA-compliant sites in Europe. The study remains on track to complete recruitment by the end of 2020. The result of a planned interim safety review by the study's Independent Safety Monitoring Board is expected to be announced in August 2020.
#DEST ''New Model Anti-Infectives'' - Destiny Pharma is not just developing novel anti-infective drugs - its lead product XF-73 is in the US and European Phase 2b study for a new preventative indication that had not been awarded to any other drug before. The clinical study of XF-73, which has proven antimicrobial activity, is expected to report an interim review in August 2020. As anti-infectives have higher probabilities of success than other therapeutic areas, Destiny’s destiny looks bright. Many august healthcare organisations such as the World Health Organisation and US Centers for Disease Control and Prevention have warned about the shortage of new antimicrobial agents to fight the global threat of antimicrobial resistance (AMR). However, many biotech companies have fallen into the trap of developing new anti-infective treatments in indications where there is no unmet medical need, or where generic competition already exists. Destiny Pharma’s novel first drug neatly side-steps all of these issues by developing XF-73 for the prevention of post-surgical staphylococcal infections. Destiny’s fruitful discussions with the FDA have resulted in recruitment recommencing in earnest and is now up to 77 patients. A smart protocol adaption has been agreed which reduces enrolment to 125 patients without compromising the power of the study’s primary endpoint. The study is now about two thirds enrolled. This is a positive development since it saves Destiny money and time; and should ensure recruitment completion by the end of 2020. We use a risk-adjusted NPV model to value Destiny Pharma based only on the development costs, our expectations of future milestone and licensing revenues for XF-73, and Destiny’s cash. Our fair value of Destiny Pharma is £86.3m or 197p per share. - click here for full noteL:
RNS Number: 0926 U Destiny Pharma PLC 27 July 2020 Destiny Pharma plc. Update on Phase 2 b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections. Brighton, United Kingdom- 27 July 2020- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that...
Destiny Pharma notes launch of $1 billion pharma-backed fund to develop new anti-infectives. Brighton, United Kingdom- 15 July 2020- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance, notes the launch of the...
RNS Number: 5155 Q Destiny Pharma PLC 19 June 2020 19 June 2020. Brighton, United Kingdom- 19 June 2020- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance, announces that on 18 June 2020, the Company cancelled options over 150,000 new...
RNS Number: 5597 P Destiny Pharma PLC 10 June 2020. Brighton, United Kingdom- 10 June 2020- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance, announces that all resolutions proposed to shareholders at the...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    43.87M

Company Profile

Destiny Pharma plc is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Classification

Market Indices-
Watchlist